Have Histological or cytologically proven diagnosis of locally advanced, unresectable, and/or metastatic cancer and measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
Have evidence of KRAS G12D mutation in tumor tissue or circulating tumor DNA
Have an ECOG performance status of ≤ 1
Must have received ≥ 1 prior line of systemic chemotherapy for advanced or metastatic disease
Participants with asymptomatic or treated CNS disease may be eligible.
You may not be if
Have known active CNS metastases and/or carcinomatous meningitis.
Have any unresolved toxicities from prior therapy greater than National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v5.0 Grade 1.
Have significant cardiovascular disease as unstable angina or acute coronary syndrome, history of myocardial infarction, known reduced left ventricular ejection fraction.
Have active uncontrolled systemic bacterial, viral, fungal, or parasitic infection.
Have known active hepatitis B virus (HBV) and hepatitis C virus (HCV).
Have other active malignancy unless in remission with life expectancy greater than (\>) 2 years.
Clareo Health | MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
